Malignancy risk and screening

Alexandra Ladouceur, Ann E. Clarke, Rosalind Ramsey-Goldman, Caroline Gordon, Sasha Bernatsky

Research output: Chapter in Book/Report/Conference proceedingChapter


Several studies have provided persuasive evidence that patients with systemic lupus erythematosus (SLE) have an altered cancer risk profile when compared with the general population. SLE patients display a higher risk of certain malignancies (e.g., hematologic, lung), whereas they seem at lower risk of others (e.g., breast cancer). This altered risk is probably explained by multiple factors, including immunosuppressant drugs, susceptibility to certain viruses, genetic factors, clinical factors, race/ethnicity, immune dysregulation, cytokines, and hormonal factors.

Original languageEnglish (US)
Title of host publicationLahita’s Systemic Lupus Erythematosus
Number of pages16
ISBN (Electronic)9780128205839
StatePublished - Jan 1 2021


  • Cancer
  • Epidemiology
  • Malignancy
  • Screening
  • Systemic lupus erythematosus (SLE)

ASJC Scopus subject areas

  • General Medicine
  • General Immunology and Microbiology


Dive into the research topics of 'Malignancy risk and screening'. Together they form a unique fingerprint.

Cite this